Synopsis: Zydus Lifesciences reported strong FY26 growth with higher revenue and profit, while also announcing a 100 percent dividend on FV and ₹1,100 crore buyback at a 16% premium, reflecting confidence in its long-term business outlook. This Large-Cap Pharma Stock,...
